Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial
/in Dendritic Cells, International Publications, Malignant MelanomaDendritic cells the tumor microenvironment and the challenges for an effective antitumor vaccination
/in Dendritic Cells, International PublicationsImmunotherapy using dendritic cells against multiple myeloma: how to improve?
/in Dendritic Cells, International Publications, Multiple MyelomaNewcastle disease virus triggers autophagy in U251 glioma cells to enhance virus replication
/in Glioblastoma, International Publications, Newcastle Disease VirusTargeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice
/in Breast Cancer, Dendritic Cells, International PublicationsProstate cancer vaccines: moving therapeutic vaccination forward in the post-Provenge era
/in Dendritic Cells, International Publications, Prostate CancerOncolytic Newcastle disease virus for cancer therapy: old challenges and new directions
/in International Publications, Newcastle Disease VirusClinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma
/in Dendritic Cells, International Publications, Pancreatic CancerClinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma
/in Dendritic Cells, Gallbladder Cancer, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer